Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Plans Permanent Offices In China In Wake Of Heparin Scare

This article was originally published in PharmAsia News

Executive Summary

In the wake of a safety scare over Chinese-imported heparin API, U.S. FDA announced March 14 that it will establish permanent offices in Beijing, Guangzhou and Shanghai, staffed by eight full-time employees and five local Chinese nationals

You may also be interested in...



Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change

BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change

Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change

BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change

Shanghai FDA Signs Agreement With U.S. Law Firm To Foster International Cooperation on Drug Regulation

BEIJING - A new government think tank focused on health-sector regulatory reform and international cooperation set up by the Shanghai FDA will work closely with a U.S.-based law firm to review drug laws worldwide and to host a series of global exchanges

Related Content

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel